313 related articles for article (PubMed ID: 12699394)
21. Synthesis and opioid receptor activity of indolopropellanes.
Li F; Gaob L; Yin C; Chen J; Liu J; Xie X; Zhang A
Bioorg Med Chem Lett; 2009 Aug; 19(16):4603-6. PubMed ID: 19595591
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
Ghirmai S; Azar MR; Polgar WE; Berzetei-Gurske I; Cashman JR
J Med Chem; 2008 Mar; 51(6):1913-24. PubMed ID: 18298057
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction.
Fujii H; Osa Y; Ishihara M; Hanamura S; Nemoto T; Nakajima M; Hasebe K; Mochizuki H; Nagase H
Bioorg Med Chem Lett; 2008 Sep; 18(18):4978-81. PubMed ID: 18755589
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
Anzini M; Canullo L; Braile C; Cappelli A; Gallelli A; Vomero S; Menziani MC; De Benedetti PG; Rizzo M; Collina S; Azzolina O; Sbacchi M; Ghelardini C; Galeotti N
J Med Chem; 2003 Aug; 46(18):3853-64. PubMed ID: 12930147
[TBL] [Abstract][Full Text] [Related]
27. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
29. 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
Grundt P; Jales AR; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2003 Apr; 46(8):1563-6. PubMed ID: 12672258
[TBL] [Abstract][Full Text] [Related]
30. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
31. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
[TBL] [Abstract][Full Text] [Related]
32. High-affinity carbamate analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration.
Nagase H; Nemoto T; Matsubara A; Saito M; Yamamoto N; Osa Y; Hirayama S; Nakajima M; Nakao K; Mochizuki H; Fujii H
Bioorg Med Chem Lett; 2010 Nov; 20(21):6302-5. PubMed ID: 20850307
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationships of dynorphin a analogues modified in the address sequence.
Schlechtingen G; DeHaven RN; Daubert JD; Cassel JA; Chung NN; Schiller PW; Taulane JP; Goodman M
J Med Chem; 2003 May; 46(11):2104-9. PubMed ID: 12747782
[TBL] [Abstract][Full Text] [Related]
38. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
Neumeyer JL; Peng X; Knapp BI; Bidlack JM; Lazarus LH; Salvadori S; Trapella C; Balboni G
J Med Chem; 2006 Sep; 49(18):5640-3. PubMed ID: 16942040
[TBL] [Abstract][Full Text] [Related]
39. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
Loew GH; Lawson JA; Uyeno ET; Toll L; Frenking G; Polgar W; Ma LY; Camerman N; Camerman A
Mol Pharmacol; 1988 Sep; 34(3):363-76. PubMed ID: 2843751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
